SANUWAVE Announces Exhibition at Medica in Cooperation With State of Georgia; Visit us at Booth 16D10-8 in Hall 16
SUWANEE, GA--(Marketwired - Sep 20, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that
the company will exhibit, in conjunction with Georgia Department of Economic Development, at MEDICA in Dusseldorf, Germany on 13
-16 November 2017. SANUWAVE cordially invites you to our section of booth 16D10-8 in Hall 16. MEDICA is the world's leading trade
fair for the medical industry. SANUWAVE is using this occasion to further educate on our lead wound care product, dermaPACE® and
our industry leader for the treatment of various orthopedic conditions, orthoPACE®.
"We are very excited about our growing activities in Europe in both the wound care and orthopedic arenas," stated Mr.
Richardson, Chief Executive Officer of SANUWAVE. "Our exhibition will be the springboard to re-establish and continue to grow our
market presence in the European Community."
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave
technology company initially focused on the development and commercialization of patented noninvasive, biological response
activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio
of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new
vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration.
SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its
lead product candidate for the global wound care market, dermaPACE, is CE Marked throughout Europe and has device license
approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE
is currently under the FDA's de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE
researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its
technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow
(lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic
tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE®
devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave
technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development
activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical
fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that
any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which
are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking
statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition
are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven
pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource
issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange
Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com .